Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess weight stability, functional changes, and quality of
life when Pancreaze (pancrelipase) delayed-release 84,000-lipase units (capsules), for main
meals, and 42,000-lipase units (capsules), for snacks, are added to standard of care in
patients with exocrine pancreatic insufficiency due to pancreatic adenocarcinoma. This will
be the first prospective study of this particular formulation in addition to standard of care
in advanced pancreatic cancer patients. We will treat 45 consecutive patients with borderline
resectable, locally advanced and advanced pancreatic cancer patients who present with weight
loss and exocrine pancreatic insufficiency with this advanced formulation of Pancreaze.